FKBP4 and prostate carcinoma: We found that the PPIase inhibitor suppressed the proliferation of both androgen‐dependent (LNCaP) and androgen‐insensitive prostate cancer cells (LNCap AI) (Fig. 1D), suggesting that the PPIase activity of FKBP51 is essential for cell proliferation in addition to AR regulation.